REWIRE: Real-world Engagement With Interventional and Rejoyn Effectiveness (NCT07792252)
A Prospective Observational Real-World Evidence Study of a 510(k)-Cleared Prescription Digital Therapeutic in Patients Receiving Interventional Treatment for Major Depressive Disorder
🩺 Plain-English Summary (8th-Grade Level)
Rejoyn is a Prescription Digital Therapeutic (PDT) for adults with Major Depressive Disorder (MDD). This study aims to evaluate the feasibility, engagement, and clinical context of integrating Rejoyn into standard interventional workflows at the Yale New Haven Hospital Interventional Psychiatry Service (IPS). This is a non-significant risk, observational real-world evidence (RWE) study.
Who can join: Review the eligibility criteria below.
Location: Yale Greenwich Hospital Interventional Psychiatry Services — Greenwich, Connecticut
Age range: 22 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- Yale Greenwich Hospital Interventional Psychiatry Services — Greenwich, Connecticut
- Yale New Haven Hospital Interventional Psychiatry Services — New Haven, Connecticut
📞 Contact the Study Coordinator
Phone: (203) 764-9131
Email: morgan.hardy@yale.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Major Depressive Disorder (MDD)
- Emotional Cognition: Establishing Constructs and Neural-Behavioral Mechanisms in Older Adults With Depression — Arlington, Texas
- Neuroimaging Markers of Midlife Depression and Cognitive Behavioural Therapy (CBT) — Toronto, Ontario
- Understanding the Role of the Kappa Opioid Receptor in Ketamine's Attenuation of Suicidal Thoughts — New York, New York
- Ketogenic Diet and Neuromodulation in Treatment Resistant Depression — Toronto, Ontario
- Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder — Toronto, Ontario
Explore by condition: All Major Depressive Disorder (MDD) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.